In particular, while immunohistochemical staining has repeatedly been shown to be reliable for detecting the IDH1 R132H variant, with reported sensitivity around 94%, specificity of up to 100%, and concordance of 98% with sequencing [11, 12, 15, 25, 26, 37], 10% of IDH mutations in infiltrating gliomas are non-R132H variants and will therefore be missed by IHC alone. Here, IDH1 is linked to central nervous system cancer.